Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Methylprednisolone
Drug ID BADD_D01433
Description Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone].[A188811] It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957.[L10785] In the outbreak of COVID-19, low dose methylprednisolone-based therapy was successful in treating COVID-19-associated pneumonia in one patient with long-term immunosuppression.[A192813] The efficacy of methylprednisolone in novel coronavirus pneumonia is being investigated further in clinical trials.[L12666]
Indications and Usage Oral and intramuscular methylprednisolone are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, respiratory, hematologic, neoplastic, edematous, gastrointestinal, nervous system, and other disorders.[L10785,L10788] Intra-articular and soft tissue injections are indicated for short term treatment of acute gouty arthritis, acute and subactute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, and synovitis of osteoarthritis.[L10788] Intralesional injections are indicated for alopecia areata, discoid lupus erythematosus, keloids, lichen planus, lichen simplex chronicus and psoriatic plaques, necrobiosis lipoidica diabeticorum, and localized hypertrophic infiltrated inflammatory lesions of granuloma annulare.[L10788]
Marketing Status approved; vet_approved
ATC Code D07AA01; D10AA02; H02AB04
DrugBank ID DB00959
KEGG ID D00407
MeSH ID D008775
PubChem ID 6741
TTD Drug ID D08PIQ
NDC Product Code 72647-331; 0781-5022; 80425-0230; 59746-003; 59762-0049; 63187-160; 71205-453; 0603-4593; 82094-402; 60722-1003; 64958-0084; 55289-649; 59762-4440; 63629-2218; 68001-557; 68001-560; 80425-0242; 22552-0029; 0009-0056; 45865-104; 59762-0050; 59762-0051; 60760-373; 63187-802; 65162-871; 68071-5221; 70121-1000; 59746-015; 65162-982; 68001-005; 68071-4028; 68084-149; 68788-4593; 71205-054; 72189-264; 82094-401; 45865-417; 50090-3094; 59746-002; 63629-2433; 68001-558; 68180-686; 69306-400; 70518-3622; 82094-403; 59746-001; 68071-2301; 68180-687; 70518-2982; 70771-1348; 70771-1349; 80425-0255; 0009-0073; 49999-153; 53002-3120; 63629-2226; 68001-559; 68180-685; 68180-688; 68382-917; 68382-918; 68382-919; 70771-1350; 80425-0231; 0904-6914; 49452-4686; 51552-0603; 0009-0020; 42806-400; 65162-984; 68180-689; 68382-916; 68788-8276; 69306-004; 70121-1001; 70771-1351; 76420-041; 82298-118; 76420-193; 82094-404; 82094-405; 51927-0201; 0009-0022; 65162-980; 68071-2745; 68788-7833; 0009-0038; 57582-011; 0009-0176; 57582-101
UNII X4W7ZR7023
Synonyms Methylprednisolone | Metipred | 6-Methylprednisolone | 6 Methylprednisolone | Urbason | Medrol
Chemical Information
Molecular Formula C22H30O5
CAS Registry Number 83-43-2
SMILES CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Petechiae24.07.06.004; 23.06.01.003; 01.01.03.0020.000189%Not Available
Phaeochromocytoma16.24.02.004; 05.01.04.0040.000032%Not Available
Pharyngeal oedema10.01.05.016; 23.04.01.016; 22.04.05.0030.000189%Not Available
Phlebitis24.12.03.004; 12.02.01.0020.000070%
Photophobia17.17.02.006; 06.01.01.0040.000166%
Pituitary-dependent Cushing's syndrome24.08.04.009; 14.11.01.055; 05.03.01.004--Not Available
Pneumothorax22.05.02.0030.000080%
Pollakiuria20.02.02.0070.000102%
Polyarthritis15.01.01.005--Not Available
Pre-existing condition improved08.01.03.0430.000109%Not Available
Premature delivery18.07.01.006--
Presyncope02.11.04.013; 24.06.02.010; 17.02.05.0090.000128%
Proctalgia07.03.02.0010.000032%
Productive cough22.02.03.005--
Prostatitis21.09.01.0010.000032%Not Available
Proteinuria20.02.01.011--
Pruritus23.03.12.0010.002599%
Pseudolymphoma01.09.01.0160.000048%Not Available
Psoriasis23.03.14.002; 10.02.01.036--Not Available
Psychomotor hyperactivity19.11.02.003; 17.01.02.0110.000150%Not Available
Psychotic behaviour19.03.01.003--Not Available
Pulmonary alveolar haemorrhage24.07.01.015; 22.01.02.0050.000080%Not Available
Pulmonary fibrosis22.01.02.0060.000032%
Pulmonary haemorrhage22.12.01.009; 24.07.01.0160.000064%
Pulmonary infarction24.04.09.001; 22.06.02.0020.000048%Not Available
Pulmonary oedema22.01.03.003; 02.05.02.003--
Purpura01.01.04.003; 24.07.06.005; 23.06.01.0040.000086%
Pyoderma gangrenosum23.07.03.001; 16.32.03.005; 10.04.02.0090.000032%Not Available
Pyrexia08.05.02.0030.001768%
Radiculopathy17.10.01.0050.000048%
The 13th Page    First    Pre   13 14 15 16 17    Next   Last    Total 22 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene